For instance, by demonstrating that the inhibition of KAT2A downregulates BETi resistance-related pathways and sensitizes melanoma to BETis, our research suggests a potential strategy to enhance the effectiveness of BETi treatment in melanoma patients. The gene discussed is KAT2A; the disease is melanoma.